Tarsus Pharmaceuticals (TARS) News Today $49.12 +0.40 (+0.82%) Closing price 04:00 PM EasternExtended Trading$49.04 -0.07 (-0.15%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period 77,714 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Acquired by Federated Hermes Inc.Federated Hermes Inc. acquired a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 77,714 shares of the company's stock, valued at approximatApril 15 at 4:48 AM | marketbeat.comAdvisory Services Network LLC Purchases 22,648 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Advisory Services Network LLC boosted its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 59.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 60,459 sharApril 13 at 5:55 AM | marketbeat.comWellington Management Group LLP Has $7.57 Million Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Wellington Management Group LLP reduced its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 5.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 136,795 shares of the company's stock after selling 8,552 shares during the quartApril 13 at 4:19 AM | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 7.2% - Should You Sell?Tarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 7.2% - Should You Sell?April 11, 2025 | marketbeat.comCapula Management Ltd Makes New Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Capula Management Ltd purchased a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 6,396 shares of the company's stoApril 10, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by Vanguard Group Inc.Vanguard Group Inc. raised its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 0.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,115,162 shares ofApril 10, 2025 | marketbeat.comDianne WhitfieldApril 10, 2025 | latimes.comAtika Capital Management LLC Acquires New Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Atika Capital Management LLC bought a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 177,200 shares of the company's stock, valueApril 8, 2025 | marketbeat.comKLP Kapitalforvaltning AS Invests $299,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)KLP Kapitalforvaltning AS bought a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 5,400 shares of the company's stock, valued at approximately $299,000. OtherApril 8, 2025 | marketbeat.comSei Investments Co. Purchases 12,689 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Sei Investments Co. grew its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 35.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 48,180 shares of the company's stock after acquiring an additional 12,689 shares during thApril 6, 2025 | marketbeat.comRaymond James Financial Inc. Makes New $1.11 Million Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Raymond James Financial Inc. acquired a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 19,999 shares of the company's stock, valued at approximaApril 5, 2025 | marketbeat.comBlair William & Co. IL Makes New $1.51 Million Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Blair William & Co. IL acquired a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 27,230 shares of the company's stock, valued at approximately $1,508,000. BlaApril 4, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of "Buy" by BrokeragesTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) has been given an average recommendation of "Buy" by the seven ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one hasApril 4, 2025 | marketbeat.comAIGH Capital Management LLC Grows Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)AIGH Capital Management LLC increased its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 9.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 224,713 shares of the company's stockMarch 31, 2025 | marketbeat.comPrudential Financial Inc. Boosts Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Prudential Financial Inc. lifted its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 43.7% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 148,735 shares of the company's stock after buying an aMarch 31, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Artisan Partners Limited PartnershipArtisan Partners Limited Partnership reduced its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 2.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 691,299 shares of the comMarch 30, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Bobak R. Azamian Sells 6,000 SharesTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) CEO Bobak R. Azamian sold 6,000 shares of the business's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $50.00, for a total transaction of $300,000.00. Following the sale, the chief executive officer now directly owns 824,106 shares of the company's stock, valued at approximately $41,205,300. The trade was a 0.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.March 27, 2025 | marketbeat.comInsider Selling: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Sells 6,000 Shares of StockMarch 27, 2025 | insidertrades.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Opthea Limited Sponsored ADR (OPT) and Larimar Therapeutics (LRMR)March 25, 2025 | markets.businessinsider.comTarsus Pharmaceuticals (NASDAQ:TARS) Shares Down 2.9% - Time to Sell?Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Down 2.9% - What's Next?March 25, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Insider Sells $107,085.07 in StockTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Dianne C. Whitfield sold 2,137 shares of the company's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $50.11, for a total transaction of $107,085.07. Following the completion of the transaction, the insider now owns 46,355 shares in the company, valued at $2,322,849.05. This represents a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.March 21, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Insider Dianne C. Whitfield Sells 2,315 SharesTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Dianne C. Whitfield sold 2,315 shares of Tarsus Pharmaceuticals stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $107,161.35. Following the sale, the insider now owns 50,751 shares of the company's stock, valued at approximately $2,349,263.79. This represents a 4.36 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 21, 2025 | marketbeat.comBryan Wahl Sells 3,084 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) StockTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) General Counsel Bryan Wahl sold 3,084 shares of the business's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $50.11, for a total transaction of $154,539.24. Following the completion of the transaction, the general counsel now owns 51,712 shares in the company, valued at $2,591,288.32. The trade was a 5.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.March 21, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Sells $154,654.89 in StockTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) General Counsel Bryan Wahl sold 3,341 shares of the company's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $154,654.89. Following the sale, the general counsel now owns 58,057 shares of the company's stock, valued at approximately $2,687,458.53. This trade represents a 5.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.March 21, 2025 | marketbeat.comBobak R. Azamian Sells 7,131 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) StockTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) CEO Bobak R. Azamian sold 7,131 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $330,093.99. Following the completion of the transaction, the chief executive officer now directly owns 70,720 shares in the company, valued at $3,273,628.80. The trade was a 9.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.March 21, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Bobak R. Azamian Sells 8,534 SharesTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) CEO Bobak R. Azamian sold 8,534 shares of the stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total transaction of $427,638.74. Following the transaction, the chief executive officer now owns 53,635 shares in the company, valued at $2,687,649.85. This trade represents a 13.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 21, 2025 | marketbeat.comDianne C. Whitfield Sells 2,137 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) StockMarch 21, 2025 | insidertrades.comTarsus Pharmaceuticals 2.809M share Spot Secondary priced at $44.50March 13, 2025 | markets.businessinsider.comTarsus prices $125M stock offeringMarch 13, 2025 | msn.comTarsus Pharmaceuticals announces $100M common stock offeringMarch 12, 2025 | markets.businessinsider.comTarsus Announces Pricing of Upsized $125.0 Million Public OfferingMarch 12, 2025 | globenewswire.comTarsus Announces Proposed $100.0 Million Public OfferingMarch 12, 2025 | globenewswire.comTarsus Pharma: Strong Execution In Xdemvy CommercializationMarch 11, 2025 | seekingalpha.comPacira Pharmaceuticals (PCRX) Receives a Hold from BarclaysMarch 10, 2025 | markets.businessinsider.comEssex Investment Management Co. LLC Decreases Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Essex Investment Management Co. LLC trimmed its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 26.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 79,760March 10, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Buy" by BrokeragesShares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have received a consensus recommendation of "Buy" from the seven research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, five have given a bMarch 9, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc.March 8, 2025 | cnn.comTarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Up 5.8% After Analyst UpgradeTarsus Pharmaceuticals (NASDAQ:TARS) Shares Up 5.8% Following Analyst UpgradeMarch 8, 2025 | marketbeat.comLisanti Capital Growth LLC Has $5.37 Million Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Lisanti Capital Growth LLC increased its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 143.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 96,935 shares of the company's stoMarch 8, 2025 | marketbeat.comAigen Investment Management LP Purchases New Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Aigen Investment Management LP purchased a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 7,504 shares of the company's stock, valued atMarch 8, 2025 | marketbeat.comJefferies Financial Group Issues Positive Forecast for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock PriceJefferies Financial Group increased their target price on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a report on Thursday.March 7, 2025 | marketbeat.comTarsus to Participate in Upcoming Investor ConferenceMarch 6, 2025 | globenewswire.comTarsus Pharmaceuticals price target raised to $58 from $54 at JefferiesMarch 6, 2025 | markets.businessinsider.comSeattle biotech launches with $187 million for cancer treatmentsMarch 4, 2025 | bizjournals.comOppenheimer Keeps Their Buy Rating on Apellis Pharmaceuticals (APLS)March 3, 2025 | markets.businessinsider.comARS Pharmaceuticals (SPRY) Receives a Buy from William BlairMarch 3, 2025 | markets.businessinsider.comWhat is HC Wainwright's Forecast for TARS Q1 Earnings?Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Tarsus Pharmaceuticals in a research note issued on Wednesday, February 26th. HC Wainwright analyst O. Livnat expects that the company will earn ($0.80) perMarch 1, 2025 | marketbeat.comLifesci Capital Weighs in on TARS Q1 EarningsTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Stock analysts at Lifesci Capital issued their Q1 2025 earnings per share estimates for shares of Tarsus Pharmaceuticals in a report issued on Wednesday, February 26th. Lifesci Capital analyst C. Jubinville anticipates that the company wiMarch 1, 2025 | marketbeat.comWilliam Blair Issues Pessimistic Outlook for TARS EarningsTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Research analysts at William Blair dropped their Q1 2025 EPS estimates for Tarsus Pharmaceuticals in a report issued on Tuesday, February 25th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings of ($March 1, 2025 | marketbeat.comQ1 Earnings Forecast for TARS Issued By William BlairTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Equities researchers at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Tarsus Pharmaceuticals in a research report issued to clients and investors on Tuesday, February 25th. William Blair analyst L. HaFebruary 28, 2025 | marketbeat.com Remove Ads Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address TARS Media Mentions By Week TARS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TARS News Sentiment▼1.270.78▲Average Medical News Sentiment TARS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TARS Articles This Week▼84▲TARS Articles Average Week Remove Ads Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Roivant Sciences News Lantheus News Revolution Medicines News BridgeBio Pharma News TG Therapeutics News Legend Biotech News Telix Pharmaceuticals Limited American Depositary Shares News Sarepta Therapeutics News Blueprint Medicines News Axsome Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TARS) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
